Enhances BCL10-induced activation of NF-kappa-B. Involved in nuclear export of BCL10. Binds to TRAF6, inducing TRAF6 oligomerization and activation of its ligase activity. Has ubiquitin ligase activity. MALT1-dependent BCL10 cleavage plays an important role in T-cell antigen receptor-induced integrin adhesion. Binds through its Ig-like domains to BCL10. Forms oligomers which bind to TRAF6. Highly expressed in peripheral blood mononuclear cells. Detected at lower levels in bone marrow, thymus and lymph node, and at very low levels in colon and lung. Belongs to the peptidase C14B family. 2 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: EC 3.4.22.-; Apoptosis; Ligase; Protease; Adaptor/scaffold; Ubiquitin conjugating system
Cellular Component: CBM complex; protein complex; perinuclear region of cytoplasm; cytoplasm; plasma membrane; nucleolus; nucleus; cytosol
Molecular Function: peptidase activity; protein binding; signal transducer activity; protein self-association; protease binding; cysteine-type endopeptidase activity; ubiquitin-protein ligase activity; kinase activator activity
Biological Process: response to fungus; positive regulation of I-kappaB kinase/NF-kappaB cascade; activation of NF-kappaB-inducing kinase; nuclear export; positive regulation of T cell cytokine production; protein ubiquitination; defense response; proteolysis; T cell receptor signaling pathway; protein oligomerization; activation of NF-kappaB transcription factor; T cell proliferation; regulation of apoptosis; B-1 B cell differentiation; positive regulation of protein ubiquitination; regulation of T cell receptor signaling pathway; response to molecule of bacterial origin; positive regulation of interleukin-2 production; innate immune response; positive regulation of T cell activation; negative regulation of apoptosis
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.